ST. JOSEPH, Mich., March 23 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the Indiana Clinical and Translational Sciences Institute (CTSI) has licensed its pathway analysis suite MetaCore and its database searching tool Eureka. The CTSI is based on a $25 million National Institutes of Health Clinical and Translational Science Award (CTSA) and is a partnership between Indiana University, Purdue University, and the University of Notre Dame. GeneGo will embed its Eureka platform into the CTSI website for use by all CTSI researchers.
The CTSI portal, called the Indiana CTSI HUB (http://www.indianactsi.org/), is a content management system that is designed to be the central clearinghouse for translational research activities for health care researchers at the IU School of Medicine and ultimately across the state of Indiana. The goals of the CTSI are to create research acceleration programs and support pilot projects, train a new cadre of translational researchers, foster robust community engagement, build facile and comprehensive resources and technologies, and leverage the resources of the greater Indiana community.
"A primary goal of the Indiana CTSI Translational Technologies Program (TTR) is to build an infrastructure that enhances the opportunity for our researchers to utilize state-of-the-art technologies. GeneGo's agreement to provide access to their software tools to all investigators across our partner institutions at a cost equivalent to that for a few researchers to purchase their own agreements significantly contributes to this goal and offers an expanded opportunity for inter-campus collaborations," said Lilith Reeves, Chief Scientific Officer, Indiana CTSI, IUSM. The partner institutions include the Indiana University School of Medicine, Purdue University, University of Notre Dame, Indiana University Bloomington, and Indiana University-Purdue University Indianapolis.
"Eureka is an easy to use 'Google-like' interface that allows researchers to leverage the excellent quality of GeneGo's database in their everyday workflows," said Julie Bryant, VP of Sales and Business Development at GeneGo. "Indiana is on the cutting edge of translational research with its excellent universities and we are pleased to be a part of this."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.1™, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.1™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.
SOURCE GeneGo, Inc.Back to top
|SOURCE GeneGo, Inc.|
Copyright©2010 PR Newswire.
All rights reserved